drugset / Trial / NCT01433419

Open-label Study of TAK-875

NCT01433419

Phase 3 Completed 333 enrolled Takeda
Parallel-group

Summary

The purpose of this study is to evaluate the safety and efficacy of treatment with TAK-875 in diabetic patients.

Timeline

Start
2012-01
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasiglifam Small molecule 25 mg
Subject Fasiglifam Small molecule 50 mg

Indications